Any feedback?
Please rate this page
(enzyme.php)
(0/150)

BRENDA support

Disease on EC 3.1.4.2 - glycerophosphocholine phosphodiesterase

Please use the Disease Search for a specific query.
Please wait a moment until all data is loaded. This message will disappear when all data is loaded.
DISEASE
TITLE OF PUBLICATION
LINK TO PUBMED
Abortion, Missed
Serum Levels of Collectins Are Sustained During Pregnancy: Surfactant Protein D Levels Are Dysregulated Prior to Missed Abortion.
Acquired Immunodeficiency Syndrome
AIDS patients have increased surfactant protein D but normal mannose binding lectin levels in lung fluid.
Acute Kidney Injury
Innate immune molecule surfactant protein D attenuates sepsis-induced acute kidney injury through modulating apoptosis and NF?B-mediated inflammation.
Surfactant protein D (SP-D) gene polymorphism rs721917 is an independent predictor of acute kidney injury development in sepsis patients: a prospective cohort study.
Acute Lung Injury
Anti-inflammatory and antioxidant effects of infliximab on acute lung injury in a rat model of intestinal ischemia/reperfusion.
Depletion of circulating monocytes suppresses IL-17 and HMGB1 expression in mice with LPS-induced acute lung injury.
Differential modulation of surfactant protein D under acute and persistent hypoxia in acute lung injury.
Effect of dexamethasone on the content of pulmonary surfactant protein D in young rats with acute lung injury induced by lipopolysaccharide.
Effect of Single versus Bilateral Lung Transplantation on Plasma Surfactant Protein D Levels in Idiopathic Pulmonary Fibrosis.
Lower Oligomeric Form of Surfactant Protein D in Murine Acute Lung Injury Induces M1 Subtype Macrophages Through Calreticulin/p38 MAPK Signaling Pathway.
PLASMA BIOMARKER PROFILES IN ACUTE EXACERBATION OF IDIOPATHIC PULMONARY FIBROSIS.
Prognostic value of surfactant proteins A and D in patients with acute lung injury.
Protective effect of curcumin on acute lung injury induced by intestinal ischemia/reperfusion.
Serum surfactant protein D in COVID-19 is elevated and correlated with disease severity.
Surfactant phospholipids, surfactant proteins, and inflammatory markers during acute lung injury in children.
Surfactant protein D gene regulation. Interactions among the conserved CCAAT/enhancer-binding protein elements.
Surfactant protein D is a useful biomarker for monitoring acute lung injury in rats.
Adenocarcinoma
High expression of Helicobacter pylori VapD in both the intracellular environment and biopsies from gastric patients with severity.
Alveolitis, Extrinsic Allergic
Involvement of eicosanoids and surfactant protein D in extrinsic allergic alveolitis.
Mushroom worker's lung caused by spores of Hypsizigus marmoreus (Bunashimeji): elevated serum surfactant protein D levels.
The usefulness of KL-6 and SP-D for the diagnosis and management of chronic hypersensitivity pneumonitis.
Anemia, Sickle Cell
Immunogenicity and Safety of 10-valent Pneumococcal Nontypeable Haemophilus influenzae Protein D Conjugate Vaccine (PHiD-CV) Administered to Children With Sickle Cell Disease Between 8 Weeks and 2 Years of Age: A Phase III, Open, Controlled Study.
Surfactant protein D as a marker for pulmonary complications in pediatric patients with sickle cell disease: Relation to lung function tests.
Arthritis, Rheumatoid
Circadian rhythm and the influence of physical activity on circulating surfactant protein D in early and long-standing rheumatoid arthritis.
Circulating surfactant protein D is decreased in early rheumatoid arthritis: a 1-year prospective study.
Asbestosis
Serum concentrations of Krebs von den Lungen-6, surfactant protein D, and matrix metalloproteinase-2 as diagnostic biomarkers in patients with asbestosis and silicosis: a case-control study.
Aspergillosis, Allergic Bronchopulmonary
Surfactant protein D in serum from patients with allergic bronchopulmonary aspergillosis.
Asthma
Airway surfactant protein D (SP-D) deficiency in adults with severe asthma.
Amino acid variants in Surfactant protein D are not associated with bronchial asthma.
Immunomodulatory function of surfactant protein D in eosinophilic asthma.
Impact of a Met(11)Thr single nucleotide polymorphism of surfactant protein D on allergic airway inflammation in a murine asthma model.
Increased surfactant protein D in rat airway goblet and Clara cells during ovalbumin-induced allergic airway inflammation.
Linking surfactant protein SP-D and IL-13: implications in asthma and allergy.
Mouse Strain-Dependent Difference Toward the Staphylococcus aureus Allergen Serine Protease-Like Protein D Reveals a Novel Regulator of IL-33.
Perinatal biomarkers implying 'Developmental Origins of Health and Disease' consequences in intrauterine growth restriction.
Serum Surfactant Protein D as a Marker of Asthma Severity.
Sputum and BAL Clara cell secretory protein and Surfactant protein D levels in asthma.
Surfactant protein D and asthma.
Surfactant protein D multimerization and gene polymorphism in COPD and asthma.
Therapeutic effect of surfactant protein D in allergic inflammation of mite-sensitized mice.
[The total content and oligomeric transformations of surfactant protein d in bronchoalveolar lavage fluid in bronchial asthma and gastroesophageal reflux disease: the role in deterioration of the immune response].
Atherosclerosis
Association between the surfactant protein D (SFTPD) gene and subclinical carotid artery atherosclerosis.
Serum Surfactant Protein D is Associated with Atherosclerosis of the Carotid Artery in Patients on Maintenance Hemodialysis.
Bacterial Infections
Inhibition of neutrophil elastase reduces lung injury and bacterial count in hamsters.
Blister
Surfactant protein D regulates caspase-8-mediated cascade of the intrinsic pathway of apoptosis while promoting bleb formation.
Brain Neoplasms
CRP-ductin, the mouse homologue of gp-340/deleted in malignant brain tumors 1 (DMBT1), binds gram-positive and gram-negative bacteria and interacts with lung surfactant protein D.
Breast Neoplasms
Glycerophosphodiester phosphodiesterase domain containing 5 (GDPD5) expression correlates with malignant choline phospholipid metabolite profiles in human breast cancer.
Hyaluronic Acid Present in the Tumor Microenvironment Can Negate the Pro-apototic Effect of a Recombinant Fragment of Human Surfactant Protein D on Breast Cancer Cells.
Molecular Effects of Doxorubicin on Choline Metabolism in Breast Cancer.
Silencing of the glycerophosphocholine phosphodiesterase GDPD5 alters the phospholipid metabolite profile in a breast cancer model in vivo as monitored by (31) P MRS.
Targeting choline phospholipid metabolism: GDPD5 and GDPD6 silencing decrease breast cancer cell proliferation, migration, and invasion.
Bronchiectasis
Does a 10-valent pneumococcal-Haemophilus influenzae protein D conjugate vaccine prevent respiratory exacerbations in children with recurrent protracted bacterial bronchitis, chronic suppurative lung disease and bronchiectasis: protocol for a randomised controlled trial.
Paediatric and adult bronchiectasis: Vaccination in prevention and management.
The clinical, immunological and microbiological impact of the 10-valent pneumococcal-Protein D conjugate vaccine in children with recurrent protracted bacterial bronchitis, chronic suppurative lung disease and bronchiectasis: A multi-centre, double-blind, randomised controlled trial.
Bronchiolitis Obliterans
Prognostic value of serum surfactant protein D level prior to transplant for the development of bronchiolitis obliterans syndrome and idiopathic pneumonia syndrome following allogeneic hematopoietic stem cell transplantation.
Bronchitis
Does a 10-valent pneumococcal-Haemophilus influenzae protein D conjugate vaccine prevent respiratory exacerbations in children with recurrent protracted bacterial bronchitis, chronic suppurative lung disease and bronchiectasis: protocol for a randomised controlled trial.
The clinical, immunological and microbiological impact of the 10-valent pneumococcal-Protein D conjugate vaccine in children with recurrent protracted bacterial bronchitis, chronic suppurative lung disease and bronchiectasis: A multi-centre, double-blind, randomised controlled trial.
Bronchitis, Chronic
Sequence variation in the hpd gene of nonencapsulated Haemophilus influenzae isolated from patients with chronic bronchitis.
Bronchopulmonary Dysplasia
Serum surfactant protein D as a marker for bronchopulmonary dysplasia.
Surfactant protein D and bronchopulmonary dysplasia: a new way to approach an old problem.
Carcinogenesis
Circ_0007142 downregulates miR-874-3p-mediated GDPD5 on colorectal cancer cells.
Carcinoma
Opposite effects of tumor protein D (TPD) 52 and TPD54 on oral squamous cell carcinoma cells.
Carcinoma, Non-Small-Cell Lung
Serum levels of surfactant protein D predict the anti-tumor activity of gefitinib in patients with advanced non-small cell lung cancer.
[Joint serum tumor markers serve as survival predictive model of erlotinib in the treatment of recurrent non-small cell lung cancer].
Cardiovascular Diseases
Serum surfactant protein D is associated with the prognosis in patients with chronic kidney disease.
Surfactant protein D is not so friendly outside the lung-aggravation of cardiovascular disease.
Cervical Intraepithelial Neoplasia
Phase I/II trial of immunogenicity of a human papillomavirus (HPV) type 16 E7 protein-based vaccine in women with oncogenic HPV-positive cervical intraepithelial neoplasia.
Chronic Periodontitis
Increased plasma concentration of surfactant protein D in chronic periodontitis independent of SFTPD genotype: potential role as a biomarker.
Coinfection
Intranasal coinfection model allows for assessment of protein vaccines against nontypeable Haemophilus influenzae in mice.
Colitis, Ulcerative
Genetic variants in surfactant, pulmonary-associated protein D (SFTPD) and Japanese susceptibility to ulcerative colitis.
Collagen Diseases
Comparative evaluation of KL-6 and surfactant protein D as serum markers for interstitial pneumonia associated with collagen diseases.
Colonic Neoplasms
Association of surfactant protein D with pulmonary metastases from colon cancer.
Colorectal Neoplasms
Circ_0007142 downregulates miR-874-3p-mediated GDPD5 on colorectal cancer cells.
GDPD5, a target of miR-195-5p, is associated with metastasis and chemoresistance in colorectal cancer.
Communicable Diseases
Innate Immune Molecule Surfactant Protein D Attenuates Sepsis-induced Acute Pancreatic Injury through Modulating Apoptosis and NF-?B-mediated Inflammation.
Connective Tissue Diseases
Comparative diagnostic efficacy of serum Krebs von den Lungen-6 and surfactant D for connective tissue disease-associated interstitial lung diseases: A meta-analysis.
Coronary Artery Disease
Serum surfactant protein D is associated with the prognosis in patients with chronic kidney disease.
COVID-19
Are Serum Interleukin 6 and Surfactant Protein D Levels Associated with the Clinical Course of COVID-19?
Effect of tocilizumab on clinical outcomes at 15 days in patients with severe or critical coronavirus disease 2019: randomised controlled trial.
Expression of Surfactant Protein D Distinguishes Severe Pandemic Influenza A(H1N1) from Coronavirus Disease 2019.
Serum surfactant protein D in COVID-19 is elevated and correlated with disease severity.
Cryptococcosis
Impact of surfactant protein D, interleukin-5, and eosinophilia on Cryptococcosis.
Surfactant protein D facilitates Cryptococcus neoformans infection.
Cystic Fibrosis
Genetic Association With Pseudomonas aeruginosa Acquisition in Cystic Fibrosis: Influence of Surfactant Protein D and Mannose-Binding Lectin.
Oxidative damage to surfactant protein D in pulmonary diseases.
Proteolysis of surfactant protein D by cystic fibrosis relevant proteases.
Surfactant protein D in serum from patients with allergic bronchopulmonary aspergillosis.
The potential of recombinant surfactant protein D therapy to reduce inflammation in neonatal chronic lung disease, cystic fibrosis, and emphysema.
Dementia
Serum surfactant protein D is correlated to development of dementia and augmented mortality.
Dermatitis
Auf1/Hnrnpd-deficient mice develop pruritic inflammatory skin disease.
Dermatitis, Atopic
Surfactant protein D in atopic dermatitis and psoriasis.
Dermatomyositis
Surfactant protein D is associated with 3-month mortality of anti-MDA5 antibody-interstitial lung disease.
Diabetes Mellitus, Type 2
Serum Surfactant Protein D as a Biomarker for Measuring Lung Involvement in Obese Type 2 Diabetic Patients.
Diphtheria
A physico-chemical assessment of the thermal stability of pneumococcal conjugate vaccine components.
Comparative effects of carrier proteins on vaccine-induced immune response.
Effectiveness of the ten-valent pneumococcal Haemophilus influenzae protein D conjugate vaccine (PHiD-CV10) against invasive pneumococcal disease: a cluster randomised trial.
Immunogenicity, safety, and reactogenicity of the 10-valent pneumococcal non-typeable Hemophilus influenzae protein D conjugate vaccine (PHiD-CV) when co-administered with the DTPw-HBV/Hib vaccine in Indian infants: a single-blind, randomized, controlled study.
Pneumococcal conjugated vaccine: PHiD-CV.
Preclinical Development of a Fusion Peptide Conjugate as an HIV Vaccine Immunogen.
Preclinical studies on new proteins as carrier for glycoconjugate vaccines.
Protein carriers of conjugate vaccines: Characteristics, development and clinical trials.
Safety and reactogenicity of primary vaccination with the 10-valent pneumococcal non-typeable Haemophilus influenzae protein D conjugate vaccine in Vietnamese infants: a randomised, controlled trial.
Safety of the 11-valent pneumococcal vaccine conjugated to non-typeable Haemophilus influenzae-derived protein D in the first 2 years of life and immunogenicity of the co-administered hexavalent diphtheria, tetanus, acellular pertussis, hepatitis B, inactivated polio virus, Haemophilus influenzae type b and control hepatitis A vaccines.
The short-term impact of each primary dose of pneumococcal conjugate vaccine on nasopharyngeal carriage: Systematic review and meta-analyses of randomised controlled trials.
Dry Eye Syndromes
Surfactant protein D contributes to ocular defense against pseudomonas aeruginosa in a murine model of dry eye disease.
Endometrial Neoplasms
EDI3 links choline metabolism to integrin expression, cell adhesion and spreading.
Endotoxemia
Surfactant protein d deficiency in mice is associated with hyperphagia, altered fat deposition, insulin resistance, and increased basal endotoxemia.
Surfactant Protein D Deficiency Increases Lung Injury during Endotoxemia.
Eosinophilia
Impact of surfactant protein D, interleukin-5, and eosinophilia on Cryptococcosis.
Ozone-induced enhancement of airway hyperreactivity in rhesus macaques: Effects of antioxidant treatment.
Farmer's Lung
Mushroom worker's lung caused by spores of Hypsizigus marmoreus (Bunashimeji): elevated serum surfactant protein D levels.
Fetal Growth Retardation
The Effect of Intrauterine Growth Restriction on Circulating Surfactant Protein D Concentrations in the Perinatal Period.
Fibroma
[Chondromyxoid fibroma]
Gastroesophageal Reflux
[Clinical value of surfactant protein D as a biomarker of pulmonary fibrosis in patients with scleroderma systematica in relation to the presence of gastroesophageal reflux].
[The total content and oligomeric transformations of surfactant protein d in bronchoalveolar lavage fluid in bronchial asthma and gastroesophageal reflux disease: the role in deterioration of the immune response].
glycerophosphocholine phosphodiesterase deficiency
Surfactant Protein D Deficiency Aggravates Cigarette Smoke-Induced Lung Inflammation by Upregulation of Ceramide Synthesis.
Surfactant protein d deficiency in mice is associated with hyperphagia, altered fat deposition, insulin resistance, and increased basal endotoxemia.
Surfactant Protein D Deficiency Increases Lung Injury during Endotoxemia.
Surfactant protein D deficiency influences allergic immune responses.
Glycogen Storage Disease Type VI
Rapidly progressive organizing pneumonia associated with COVID-19.
Hearing Loss
Identification of Novel Candidate Genes and Variants for Hearing Loss and Temporal Bone Anomalies.
Helicobacter Infections
Helicobacter infection in the surfactant protein D-deficient mouse.
Hemorrhagic Fever, Ebola
Involvement of Surfactant Protein D in Ebola Virus Infection Enhancement via Glycoprotein Interaction.
Hepatitis A
Pneumococcal capsular polysaccharides conjugated to protein D for prevention of acute otitis media caused by both Streptococcus pneumoniae and non-typable Haemophilus influenzae: a randomised double-blind efficacy study.
Safety and immunogenicity of the 10-valent pneumococcal nontypeable Haemophilus influenzae protein D conjugate vaccine (PHiD-CV) in Chilean children.
Safety of the 11-valent pneumococcal vaccine conjugated to non-typeable Haemophilus influenzae-derived protein D in the first 2 years of life and immunogenicity of the co-administered hexavalent diphtheria, tetanus, acellular pertussis, hepatitis B, inactivated polio virus, Haemophilus influenzae type b and control hepatitis A vaccines.
Hepatitis B
Immunogenicity, safety, and reactogenicity of the 10-valent pneumococcal non-typeable Hemophilus influenzae protein D conjugate vaccine (PHiD-CV) when co-administered with the DTPw-HBV/Hib vaccine in Indian infants: a single-blind, randomized, controlled study.
Long-term immunogenicity and immune memory response to the hepatitis B antigen in the RTS,S/AS01E malaria vaccine in African children: a randomized trial.
Safety and reactogenicity of primary vaccination with the 10-valent pneumococcal non-typeable Haemophilus influenzae protein D conjugate vaccine in Vietnamese infants: a randomised, controlled trial.
Safety of the 11-valent pneumococcal vaccine conjugated to non-typeable Haemophilus influenzae-derived protein D in the first 2 years of life and immunogenicity of the co-administered hexavalent diphtheria, tetanus, acellular pertussis, hepatitis B, inactivated polio virus, Haemophilus influenzae type b and control hepatitis A vaccines.
Hepatitis C
Efficient display of an HCV cDNA expression library as C-terminal fusion to the capsid protein D of bacteriophage lambda.
Hepatitis E
New route for fast detection of antibodies against zoonotic pathogens in sera of slaughtered pigs by means of flow-through chemiluminescence immunochips.
Herpes Zoster
Interactions between rat alveolar epithelial cells and bone marrow-derived mesenchymal stem cells: an in vitro co-culture model.
HIV Infections
HIV Infection and Circulating Levels of Prosurfactant Protein B and Surfactant Protein D.
Surfactant Protein D Modulates HIV Infection of Both T-Cells and Dendritic Cells.
Hypersensitivity
Linking surfactant protein SP-D and IL-13: implications in asthma and allergy.
Protective effects of a recombinant fragment of human surfactant protein D in a murine model of pulmonary hypersensitivity induced by dust mite allergens.
Recombinant Fragment of Human Surfactant Protein D: A Hierarchical Regulator of Pulmonary Hypersensitivity.
Surfactant protein D in serum from patients with allergic bronchopulmonary aspergillosis.
Surfactant protein SP-D modulates activity of immune cells: proteomic profiling of its interaction with eosinophilic cells.
Idiopathic Interstitial Pneumonias
Clarithromycin mitigates radiation pneumonitis in patients with lung cancer treated with stereotactic body radiotherapy.
Idiopathic Pulmonary Fibrosis
Advances in the study of biomarkers of idiopathic pulmonary fibrosis in Japan.
Comparative Proteomic Analysis of Rat Bronchoalveolar Lavage Fluid after Exposure to Zinc Oxide Nanoparticles.
Concentration of surfactant protein D, Clara cell protein CC-16 and IL-10 in bronchoalveolar lavage (BAL) in patients with sarcoidosis, hypersensivity pneumonitis and idiopathic pulmonary fibrosis.
Effect of Single versus Bilateral Lung Transplantation on Plasma Surfactant Protein D Levels in Idiopathic Pulmonary Fibrosis.
Increased circulating levels of soluble Fas ligand are correlated with disease activity in patients with fibrosing lung diseases.
Letter to the Editor: Serum surfactant protein D predicts the outcome of patients with idiopathic pulmonary fibrosis treated with pirfenidone.
PLASMA BIOMARKER PROFILES IN ACUTE EXACERBATION OF IDIOPATHIC PULMONARY FIBROSIS.
Prognostic significance of surfactant protein A, surfactant protein D, Clara cell protein 16, S100 protein, trefoil factor 3, and prostatic secretory protein 94 in idiopathic pulmonary fibrosis, sarcoidosis, and chronic pulmonary obstructive disease.
Serum surfactant protein D as a predictive biomarker for the efficacy of pirfenidone in patients with idiopathic pulmonary fibrosis: a post-hoc analysis of the phase 3 trial in Japan.
Serum surfactant protein D predicts the outcome of patients with idiopathic pulmonary fibrosis treated with pirfenidone.
Surfactant protein D and KL-6 as serologic indicators of Pneumocystis carinii pneumonia in a child with acute lymphoblastic leukemia.
Infections
A Unique Sugar-binding Site Mediates the Distinct Anti-influenza Activity of Pig Surfactant Protein D.
Altered Gut Microbiota Composition in Subjects Infected With Clonorchis sinensis.
Characterization of two lipoproteins in Pasteurella multocida.
Chlamydia psittaci PmpD-N Exacerbated Chicken Macrophage Function by Triggering Th2 Polarization and the TLR2/MyD88/NF-?B Signaling Pathway.
Clinical significance of the serum surfactant protein D and KL-6 levels in patients with measles complicated by interstitial pneumonia.
Differential expression of ovine innate immune genes by preterm and neonatal lung epithelia infected with respiratory syncytial virus.
Dipeptidyl peptidase I controls survival from Klebsiella pneumoniae lung infection by processing surfactant protein D.
Effectiveness of the ten-valent pneumococcal Haemophilus influenzae protein D conjugate vaccine (PHiD-CV10) against all respiratory tract infections in children under two years of age.
Effects on the ciliated epithelium of protein D-producing and -nonproducing nontypeable Haemophilus influenzae in nasopharyngeal tissue cultures.
Engineered phage-based therapeutic materials inhibit Chlamydia trachomatis intracellular infection.
Enhanced Antiviral Activity of Human Surfactant Protein D by Site-Specific Engineering of the Carbohydrate Recognition Domain.
Expression of surfactant protein D in the human gastric mucosa and during Helicobacter pylori infection.
Functional Analysis of Genetic Variations in Surfactant Protein D in Mycobacterial Infection and Their Association With Tuberculosis.
Histone H4 potentiates neutrophil inflammatory responses to influenza A virus: Down-modulation by H4 binding to C-reactive protein and Surfactant protein D.
Immunogenicity and Safety of 10-valent Pneumococcal Nontypeable Haemophilus influenzae Protein D Conjugate Vaccine (PHiD-CV) Administered to Children With Sickle Cell Disease Between 8 Weeks and 2 Years of Age: A Phase III, Open, Controlled Study.
Impact of neutrophils on antiviral activity of human bronchoalveolar lavage fluid.
In vivo evaluation of adeno-associated virus gene transfer in airways of mice with acute or chronic respiratory infection.
Inhibition of competence development, horizontal gene transfer and virulence in Streptococcus pneumoniae by a modified competence stimulating peptide.
Innate defense against influenza A virus: activity of human neutrophil defensins and interactions of defensins with surfactant protein D.
Innate Immunity and Influenza A Virus Pathogenesis: Lessons for COVID-19.
Lectin-mediated binding and sialoglycans of porcine surfactant protein D synergistically neutralize influenza A virus.
Linking surfactant protein SP-D and IL-13: implications in asthma and allergy.
Local and systemic antibody levels against protein D of Haemophilus influenzae following immunization and infection in rats.
Protective Role of Surfactant Protein D in Ocular Staphylococcus aureus Infection.
Pulmonary infections in swine induce altered porcine surfactant protein D expression and localization to dendritic cells in bronchial-associated lymphoid tissue.
Pulmonary surfactant phosphatidylglycerol inhibits respiratory syncytial virus-induced inflammation and infection.
Pulmonary Surfactant Protein D in First-Line Innate Defence against Influenza A Virus Infections.
Recombinant polymorphic membrane protein D in combination with a novel, second-generation lipid adjuvant protects against intra-vaginal Chlamydia trachomatis infection in mice.
Reduced influenza viral neutralizing activity of natural human trimers of surfactant protein D.
Reduced nontypeable Haemophilus influenzae lower airway infection in children with chronic endobronchial suppuration vaccinated with the 10-valent pneumococcal H. influenzae protein D conjugate vaccine.
Respiratory tract infections in diabetic and non-diabetic individuals are linked with serum surfactant protein-D.
Serine-Aspartate Repeat Protein D Increases Staphylococcus aureus Virulence and Survival in Blood.
Serum antibody response to three non-typeable Haemophilus influenzae outer membrane proteins during acute otitis media and nasopharyngeal colonization in otitis prone and non-otitis prone children.
Serum Concentrations of Antibodies against Outer Membrane Protein P6, Protein D, and T- and B-Cell Combined Antigenic Epitopes of Nontypeable Haemophilus influenzae in Children and Adults of Different Ages.
Serum KL-6 and SP-D in children with 2009 pandemic H1N1 influenza infection.
Sialylation of outer membrane porin protein D: a mechanistic basis of antibiotic uptake in Pseudomonas aeruginosa.
Structural requirements for SP-D function in vitro and in vivo: therapeutic potential of recombinant SP-D.
Surfactant Protein D Binds to Coxiella burnetii and Results in a Decrease in Interactions with Murine Alveolar Macrophages.
Surfactant protein D contributes to ocular defense against pseudomonas aeruginosa in a murine model of dry eye disease.
Surfactant protein D deficiency influences allergic immune responses.
Surfactant protein D facilitates Cryptococcus neoformans infection.
Surfactant protein D gene polymorphism associated with severe respiratory syncytial virus infection.
Surfactant protein D inhibits HIV-1 infection of target cells via interference with gp120-CD4 interaction and modulates pro-inflammatory cytokine production.
Surfactant protein D is present in the human female reproductive tract and inhibits Chlamydia trachomatis infection.
Surfactant protein SP-D modulates activity of immune cells: proteomic profiling of its interaction with eosinophilic cells.
The association of PM2.5 with airway innate antimicrobial activities of salivary agglutinin and surfactant protein D.
The Chlamydia trachomatis PmpD adhesin forms higher order structures through disulphide-mediated covalent interactions.
The production mechanism and immunosuppression effect of pulmonary surfactant protein D via toll like receptor 4 signaling pathway in human corneal epithelial cells during Aspergillus fumigatus infection.
The role of surfactant protein D in the colonisation of the respiratory tract and onset of bacteraemia during pneumococcal pneumonia.
The roles of surfactant protein D during Aspergillus fumigatus infection in human corneal epithelial cells.
VIRAL AGGREGATING AND OPSONIZING ACTIVITY IN COLLECTIN TRIMERS.
Inflammatory Bowel Diseases
Colonic Epithelial Surfactant Protein D Expression Correlates with Inflammation in Clinical Colonic Inflammatory Bowel Disease.
Genetic variants in surfactant, pulmonary-associated protein D (SFTPD) and Japanese susceptibility to ulcerative colitis.
Influenza in Birds
Decreased expression of surfactant protein D mRNA in human lungs in fatal cases of H5N1 avian influenza.
Influenza, Human
Assessment of the antiviral properties of recombinant porcine SP-D against various influenza A viruses in vitro.
Assessment of the antiviral properties of recombinant surfactant protein D against influenza B virus in vitro.
A reduced expression of surfactant protein D in the lungs of fatal influenza H1N1 cases in 2009.
Critical role for cross-linking of trimeric lectin domains of surfactant protein D in antiviral activity against influenza A virus.
Effects of Vaccination with 10-Valent Pneumococcal Non-Typeable Haemophilus influenza Protein D Conjugate Vaccine (PHiD-CV) on the Nasopharyngeal Microbiome of Kenyan Toddlers.
Enhanced Antiviral Activity of Human Surfactant Protein D by Site-Specific Engineering of the Carbohydrate Recognition Domain.
Enhancement of antiviral activity of collectin trimers through cross-linking and mutagenesis of the carbohydrate recognition domain.
Entry Inhibition and Modulation of Pro-Inflammatory Immune Response Against Influenza A Virus by a Recombinant Truncated Surfactant Protein D.
Evidence for a protective role of pulmonary surfactant protein D (SP-D) against influenza A viruses.
Expression of Surfactant Protein D Distinguishes Severe Pandemic Influenza A(H1N1) from Coronavirus Disease 2019.
Histone H4 potentiates neutrophil inflammatory responses to influenza A virus: Down-modulation by H4 binding to C-reactive protein and Surfactant protein D.
Impact of neutrophils on antiviral activity of human bronchoalveolar lavage fluid.
Increased antiviral and opsonic activity of a highly multimerized collectin chimera.
Influenza Virus Hemagglutinins H2, H5, H6, and H11 Are Not Targets of Pulmonary Surfactant Protein D: N-Glycan Subtypes in Host-Pathogen Interactions.
Innate defense against influenza A virus: activity of human neutrophil defensins and interactions of defensins with surfactant protein D.
Interactions of alpha-, beta-, and theta-defensins with influenza A virus and surfactant protein D.
Interactions of influenza A virus with sialic acids present on porcine surfactant protein D.
Interactions of recombinant human pulmonary surfactant protein D and SP-D multimers with influenza A.
Introduction of N-linked glycans in the lectin domain of surfactant protein D: impact on interactions with influenza A viruses.
Lectin-mediated binding and sialoglycans of porcine surfactant protein D synergistically neutralize influenza A virus.
Ligand specificity of human surfactant protein D: expression of a mutant trimeric collectin that shows enhanced interactions with influenza A virus.
Mechanism of binding of surfactant protein D to influenza A viruses: importance of binding to haemagglutinin to antiviral activity.
Molecular mechanisms of inhibition of influenza by surfactant protein D revealed by large-scale molecular dynamics simulation.
Monoclonal antibody-assisted structure-function analysis of the carbohydrate recognition domain of surfactant protein D.
Multimerization of surfactant protein D, but not its collagen domain, is required for antiviral and opsonic activities related to influenza virus.
Mutagenesis of surfactant protein D informed by evolution and x-ray crystallography enhances defenses against influenza A virus in vivo.
MUTATIONS FLANKING THE CARBOHYDRATE BINDING SITE OF SURFACTANT PROTEIN D CONFER ANTIVIRAL ACTIVITY FOR PANDEMIC INFLUENZA A VIRUSES.
Neuraminidase Activity and The Resistance of 2009 Pandemic H1N1 Influenza Virus to Antiviral Activity in Bronchoalveolar Fluid.
Paediatric and adult bronchiectasis: Vaccination in prevention and management.
Pulmonary Surfactant Protein D in First-Line Innate Defence against Influenza A Virus Infections.
Recognition of mannosylated ligands and influenza a virus by human surfactant protein D: contributions of an extended site and residue 343.
Recombinant porcine surfactant protein D inhibits influenza A virus replication ex vivo.
Reduced influenza viral neutralizing activity of natural human trimers of surfactant protein D.
Reduction of Streptococcus pneumoniae in upper respiratory tract cultures and a decreased incidence of related acute otitis media following introduction of childhood pneumococcal conjugate vaccines in a Swedish county.
Response to Letter to the Editor: Detection of naturally occurring antibodies against Protein D of Haemophilus influenza by Mustafa Akkoyunlu.
Role of viral hemagglutinin glycosylation in anti-influenza activities of recombinant surfactant protein D.
Serum KL-6 and SP-D in children with 2009 pandemic H1N1 influenza infection.
Structure of a truncated human surfactant protein D is less effective in agglutinating bacteria than the native structure and fails to inhibit haemagglutination by influenza A virus.
Surfactant protein A, but not surfactant protein D, is an opsonin for influenza A virus phagocytosis by rat alveolar macrophages.
Surfactant protein D enhances clearance of influenza A virus from the lung in vivo.
The ability of pandemic influenza virus hemagglutinins to induce lower respiratory pathology is associated with decreased surfactant protein D binding.
The human cathelicidin LL-37 inhibits influenza A viruses through a mechanism distinct from that of surfactant protein D or defensins.
The number and position of N-linked glycosylation sites in the hemagglutinin determine differential recognition of seasonal and 2009 pandemic H1N1 influenza virus by porcine surfactant protein D.
The Role and Molecular Mechanism of Action of Surfactant Protein D in Innate Host Defense Against Influenza A Virus.
Insulin Resistance
Surfactant protein d deficiency in mice is associated with hyperphagia, altered fat deposition, insulin resistance, and increased basal endotoxemia.
Surfactant protein d, a marker of lung innate immunity, is positively associated with insulin sensitivity.
Intellectual Disability
Identification of microduplications at Xp21.2 and Xq13.1 in neurodevelopmental disorders.
Invasive Pulmonary Aspergillosis
Protective role of lung surfactant protein D in a murine model of invasive pulmonary aspergillosis.
Therapeutic effects of recombinant forms of full-length and truncated human surfactant protein D in a murine model of invasive pulmonary aspergillosis.
Keratitis
Surfactant Protein D in Pseudomonas aeruginosa Keratitis.
Kidney Failure, Chronic
Antibody against Haemophilus influenzae protein D in patients with chronic conditions causing secondary immunodeficiency.
Leukomalacia, Periventricular
Intranasal surfactant protein D as neuroprotective rescue in a neonatal rat model of periventricular leukomalacia.
Surfactant protein D as a novel therapy for periventricular leukomalacia: is it the missing piece of the puzzle?
Lipidoses
Reversibility of pulmonary abnormalities by conditional replacement of surfactant protein D (SP-D) in vivo.
Lipoid Proteinosis of Urbach and Wiethe
Surfactant protein D. Increased accumulation in silica-induced pulmonary lipoproteinosis.
Liver Diseases
Immunolocalization of surfactant protein D in the liver from infants with cholestatic liver disease.
Lung Diseases
Candidate Gene Analysis of the Surfactant Protein D Gene in Pediatric Diffuse Lung Disease.
Clinical significance of surfactant protein D as a serum marker for evaluating pulmonary fibrosis in patients with systemic sclerosis.
Comparative evaluation of heterologous production systems for recombinant pulmonary surfactant protein D.
Does a 10-valent pneumococcal-Haemophilus influenzae protein D conjugate vaccine prevent respiratory exacerbations in children with recurrent protracted bacterial bronchitis, chronic suppurative lung disease and bronchiectasis: protocol for a randomised controlled trial.
Donor surfactant protein D (SP-D) polymorphisms are associated with lung transplant outcome.
Elevation of surfactant protein D, a pulmonary disease biomarker, in the sera of uveitis patients with sarcoidosis.
Genetic and environmental influences of surfactant protein D serum levels.
Genetic associations of surfactant protein D and angiotensin-converting enzyme with lung disease in preterm neonates.
Improving immunity to Haemophilus influenzae in children with chronic suppurative lung disease.
New developments in scleroderma interstitial lung disease.
Oxidative damage to surfactant protein D in pulmonary diseases.
Patterns of neutrophil serine protease-dependent cleavage of surfactant protein D in inflammatory lung disease.
Plasma surfactant D in patients following acute paraquat intoxication.
Reversibility of pulmonary abnormalities by conditional replacement of surfactant protein D (SP-D) in vivo.
Serum Surfactant Protein D as a Biomarker for Measuring Lung Involvement in Obese Type 2 Diabetic Patients.
Surfactant protein A and surfactant protein D variation in pulmonary disease.
Surfactant protein D in human lung diseases.
Surfactant protein D is associated with 3-month mortality of anti-MDA5 antibody-interstitial lung disease.
Surfactant Protein D Is Associated With Severe Pediatric ARDS, Prolonged Ventilation, and Death in Children With Acute Respiratory Failure.
Surfactant Protein-D: A sensitive predictor for efficiency of preoperative pulmonary rehabilitation.
The clinical, immunological and microbiological impact of the 10-valent pneumococcal-Protein D conjugate vaccine in children with recurrent protracted bacterial bronchitis, chronic suppurative lung disease and bronchiectasis: A multi-centre, double-blind, randomised controlled trial.
The evaluation of serum surfactant protein D (SP-D) levels as a biomarker of lung injury in tuberculosis and different lung diseases.
The potential of recombinant surfactant protein D therapy to reduce inflammation in neonatal chronic lung disease, cystic fibrosis, and emphysema.
Lung Diseases, Interstitial
A case of interstitial pneumonia caused by bucillamine: a study using serological markers.
A case of Wilson-Mikity syndrome with high serum KL-6 levels.
Analysis of immune reconstitution after autologous CD34+ stem/progenitor cell transplantation for systemic sclerosis: predominant reconstitution of Th1 CD4+ T cells.
Association between genetic variations in surfactant protein d and emphysema, interstitial pneumonia, and lung cancer in a Japanese population.
Can serum surfactant protein D or CC-chemokine ligand 18 predict outcome of interstitial lung disease in patients with early systemic sclerosis?
Clinical significance of serum surfactant protein D (SP-D) in patients with polymyositis/dermatomyositis: correlation with interstitial lung disease.
Clinical significance of the serum surfactant protein D and KL-6 levels in patients with measles complicated by interstitial pneumonia.
Comparative diagnostic efficacy of serum Krebs von den Lungen-6 and surfactant D for connective tissue disease-associated interstitial lung diseases: A meta-analysis.
Comparative evaluation of KL-6 and surfactant protein D as serum markers for interstitial pneumonia associated with collagen diseases.
Evaluation of usefulness in surfactant protein D as a predictor of mortality in myositis-associated interstitial lung disease.
Increased circulating levels of soluble Fas ligand are correlated with disease activity in patients with fibrosing lung diseases.
Involvement of eicosanoids and surfactant protein D in extrinsic allergic alveolitis.
KL-6, surfactant protein A and D in bronchoalveolar lavage fluid from patients with pulmonary sarcoidosis.
Pneumocyte Biomarkers KL-6 and Surfactant Protein D Reflect the Distinct Findings of High-Resolution Computed Tomography in Nonspecific Interstitial Pneumonia.
Pulmonary effects in workers exposed to indium metal: A cross-sectional study.
Radiation pneumonitis after stereotactic radiation therapy for lung cancer.
Rapidly progressive organizing pneumonia associated with COVID-19.
Serum concentration of surfactant protein D in patients with systemic sclerosis: The potential marker of the interstitial lung disease severity.
Serum KL-6 and surfactant proteins A and D in pediatric interstitial lung disease.
Surfactant protein D and KL-6 as serum biomarkers of interstitial lung disease in patients with scleroderma.
Surfactant protein D is associated with 3-month mortality of anti-MDA5 antibody-interstitial lung disease.
The usefulness of KL-6 and SP-D for the diagnosis and management of chronic hypersensitivity pneumonitis.
[Assessment of serum markers KL-6 and SP-D for interstitial pneumonia associated with connective tissue diseases]
[Valproate sodium and zonisamide associated interstitial pneumonitis in an infant]
Lung Diseases, Obstructive
Surfactant protein D in chornic obstructive pulmonary disease (COPD).
Lung Injury
A Potential Biomarker for Predicting the Risk of Radiation-Induced Fibrosis in the Lung.
Altered expression of cyclooxygenase-2, 12-lipoxygenase, inducible nitric oxide synthase-2 and surfactant protein D in lungs of patients with pulmonary injury caused by sulfur mustard.
Alveolar surfactant protein D content modulates bleomycin-induced lung injury.
Biomarkers for lung epithelium injury in occupational hexavalent chromium-exposed workers.
Efficient resolution of Pneumocystis murina infection in surfactant protein A-deficient mice following withdrawal of corticosteroid-induced immunosuppression.
Evaluation of Lung Injury in Infants with Congenital Diaphragmatic Hernia.
Intranasal Bifidobacterium longum protects against viral-induced lung inflammation and injury in a murine model of lethal influenza infection.
Lung Surfactant Protein D (SP-D) Response and Regulation During Acute and Chronic Lung Injury.
Plasma levels of surfactant protein D and KL-6 for evaluation of lung injury in critically ill mechanically ventilated patients.
Proximal promoter of the surfactant protein D gene: regulatory roles of AP-1, forkhead box, and GT box binding proteins.
Radiation-induced lung injury and inflammation in mice: role of inducible nitric oxide synthase and surfactant protein d.
Surfactant Protein D Dampens Lung Injury by Suppressing NLRP3 Inflammasome Activation and NF-?B Signaling in Acute Pancreatitis.
Surfactant Protein D Deficiency Increases Lung Injury during Endotoxemia.
Surfactant protein D in serum from patients with allergic bronchopulmonary aspergillosis.
Surfactant Protein D Is Associated With Severe Pediatric ARDS, Prolonged Ventilation, and Death in Children With Acute Respiratory Failure.
Surfactant protein D protects against acute hyperoxic lung injury.
The effectiveness of the serum surfactant protein D (Sp-D) level to indicate lung injury in pulmonary embolism.
The evaluation of serum surfactant protein D (SP-D) levels as a biomarker of lung injury in tuberculosis and different lung diseases.
[Clinical value of surfactant protein D as a biomarker of pulmonary fibrosis in patients with scleroderma systematica in relation to the presence of gastroesophageal reflux].
[Research of the biomarkers in pulmonary and extrapulmonary acute respiratory distress syndrome].
[Surfactant protein D as a biomarker for lung injury]
Lung Neoplasms
Association between genetic variations in surfactant protein d and emphysema, interstitial pneumonia, and lung cancer in a Japanese population.
Correlation analysis of surfactant protein A and surfactant protein D with lung function in exhaled breath condensate from lung cancer patients with and without COPD.
Serum levels of surfactant protein D predict the anti-tumor activity of gefitinib in patients with advanced non-small cell lung cancer.
Surfactant protein D and bronchial dysplasia in smokers at high risk of lung cancer.
Surfactant protein D suppresses lung cancer progression by downregulation of epidermal growth factor signaling.
[Expression and clinical significance of surfactant protein D mRNA in peripheral blood of lung cancer patients]
[Joint serum tumor markers serve as survival predictive model of erlotinib in the treatment of recurrent non-small cell lung cancer].
Lupus Erythematosus, Systemic
Circulating Surfactant Protein D Is Decreased in Systemic Lupus Erythematosus.
The Possible Effect of B-Cell Epitopes of Epstein-Barr Virus Early Antigen, Membrane Antigen, Latent Membrane Protein-1, and -2A on Systemic Lupus Erythematosus.
Measles
Clinical significance of the serum surfactant protein D and KL-6 levels in patients with measles complicated by interstitial pneumonia.
Immunogenicity of pneumococcal conjugate vaccine formulations containing pneumococcal proteins, and immunogenicity and reactogenicity of co-administered routine vaccines - A phase II, randomised, observer-blind study in Gambian infants.
Mycobacterium Infections
Potential of Ca(2+) in Mycobacterium tuberculosis H37Rv Pathogenesis and Survival.
Nasal Polyps
[Expression and significance of pulmonary surfactant protein D and IL-16 in allergic rhinitis and nasal polyps].
Neoplasm Metastasis
Association of surfactant protein D with pulmonary metastases from colon cancer.
Choline-releasing glycerophosphodiesterase EDI3 drives tumor cell migration and metastasis.
GDPD5, a target of miR-195-5p, is associated with metastasis and chemoresistance in colorectal cancer.
High expression of UBD correlates with epirubicin resistance and indicates poor prognosis in triple-negative breast cancer.
Neoplasms
A multi-trimeric fusion of CD40L and gp100 tumor antigen activates dendritic cells and enhances survival in a B16-F10 melanoma DNA vaccine model.
Antibody against Haemophilus influenzae protein D in patients with chronic conditions causing secondary immunodeficiency.
Biological subphenotypes of acute respiratory distress syndrome may not reflect differences in alveolar inflammation.
Blood Specimen Biomarkers of Inflammation, Matrix Degradation, Angiogenesis, and Cardiac Involvement: a Future Useful Tool in Assessing Clinical Outcomes of COPD Patients in Clinical Practice?
Choline-releasing glycerophosphodiesterase EDI3 drives tumor cell migration and metastasis.
Choline-releasing glycerophosphodiesterase EDI3 links the tumor metabolome to signaling network activities.
Circulating Plasma Biomarkers of Survival in Antifibrotic-Treated Patients With Idiopathic Pulmonary Fibrosis.
Circ_0007142 downregulates miR-874-3p-mediated GDPD5 on colorectal cancer cells.
Correlation between peripheral skeletal muscle functions and the stable phase of COPD in older patients.
EDI3 links choline metabolism to integrin expression, cell adhesion and spreading.
Effect of Driving Pressure Change During Extracorporeal Membrane Oxygenation in Adults With Acute Respiratory Distress Syndrome: A Randomized Crossover Physiologic Study.
Effect of lung surfactant collectins on bronchoalveolar macrophage interaction with Blastomyces dermatitidis: inhibition of tumor necrosis factor alpha production by surfactant protein D.
Exploration of potential prognostic biomarkers in aflibercept plus FOLFIRI in Japanese patients with metastatic colorectal cancer.
GDPD5, a choline-generating enzyme and its novel role in tumor cell migration.
Glycerophosphodiester phosphodiesterase domain containing 5 (GDPD5) expression correlates with malignant choline phospholipid metabolite profiles in human breast cancer.
High expression of UBD correlates with epirubicin resistance and indicates poor prognosis in triple-negative breast cancer.
Human SP-D Acts as an Innate Immune Surveillance Molecule Against Androgen-Responsive and Androgen-Resistant Prostate Cancer Cells.
Hyaluronic Acid Present in the Tumor Microenvironment Can Negate the Pro-apototic Effect of a Recombinant Fragment of Human Surfactant Protein D on Breast Cancer Cells.
Inflammatory parameters and pulmonary biomarkers in smokers with and without chronic obstructive pulmonary disease (COPD).
Opposite effects of tumor protein D (TPD) 52 and TPD54 on oral squamous cell carcinoma cells.
Pathological Significance and Prognostic Value of Surfactant Protein D in Cancer.
Phase I/II trial of immunogenicity of a human papillomavirus (HPV) type 16 E7 protein-based vaccine in women with oncogenic HPV-positive cervical intraepithelial neoplasia.
Serial Measurements of Circulating KL-6, SP-D, MMP-7, CA19-9, CA-125, CCL18, and Periostin in Patients with Idiopathic Pulmonary Fibrosis Receiving Antifibrotic Therapy: An Exploratory Study.
Serum levels of surfactant protein D are increased in mice with lung tumors.
Silencing of the glycerophosphocholine phosphodiesterase GDPD5 alters the phospholipid metabolite profile in a breast cancer model in vivo as monitored by (31) P MRS.
The Association between Body Mass Index and Plasma Cytokine Levels in Patients with Acute Lung Injury.
The role of total bile acid in oral secretions in ventilator-associated pneumonia.
Tumor Proteins D52 and D54 Have Opposite Effects on the Terminal Differentiation of Chondrocytes.
[Expression and clinical significance of surfactant protein D mRNA in peripheral blood of lung cancer patients]
[Systemic inflammation in patients with chronic obstructive pulmonary disease and obesity].
Neoplastic Cells, Circulating
[Expression and clinical significance of surfactant protein D mRNA in peripheral blood of lung cancer patients]
Neuroblastoma
Glycerophosphodiesterase GDE2 Promotes Neuroblastoma Differentiation through Glypican Release and Is a Marker of Clinical Outcome.
Obesity
Genetic variations of the bitter taste receptor TAS2R38 are associated with obesity and impact on single immune traits.
Least absolute shrinkage and selection operator type methods for the identification of serum biomarkers of overweight and obesity: simulation and application.
Surfactant protein D of the innate immune defence is inversely associated with human obesity and SP-D deficiency infers increased body weight in mice.
Otitis
Bactericidal antibody response against P6, protein D, and OMP26 of nontypeable Haemophilus influenzae after acute otitis media in otitis-prone children.
Experimental recurrent otitis media induced by Haemophilus influenzae: protection and serum antibodies.
Pneumococcal capsular polysaccharides conjugated to protein D for prevention of acute otitis media caused by both Streptococcus pneumoniae and non-typable Haemophilus influenzae: a randomised double-blind efficacy study.
Protein D, the glycerophosphodiester phosphodiesterase from Haemophilus influenzae with affinity for human immunoglobulin D, influences virulence in a rat otitis model.
Reduced middle ear infection with non-typeable Haemophilus influenzae, but not Streptococcus pneumoniae, after transition to 10-valent pneumococcal non-typeable H. influenzae protein D conjugate vaccine.
Serum antibody response to three non-typeable Haemophilus influenzae outer membrane proteins during acute otitis media and nasopharyngeal colonization in otitis prone and non-otitis prone children.
The Effect of the 10-Valent Pneumococcal Nontypeable Haemophilus influenzae Protein D Conjugate Vaccine on H. influenzae in Healthy Carriers and Middle Ear Infections in Iceland.
Why we need a vaccine for non-typeable Haemophilus influenzae.
Otitis Media
10-Valent pneumococcal non-typeable H. influenzae protein D conjugate vaccine (PHiD-CV10) versus 13-valent pneumococcal conjugate vaccine (PCV13) as a booster dose to broaden and strengthen protection from otitis media (PREVIX_BOOST) in Australian Aboriginal children: study protocol for a randomised controlled trial.
10-valent pneumococcal nontypeable Haemophilus influenzae PD conjugate vaccine: Synflorix.
Abrogation of nontypeable Haemophilus influenzae protein D function reduces phosphorylcholine decoration, adherence to airway epithelial cells, and fitness in a chinchilla model of otitis media.
Bactericidal antibody response against P6, protein D, and OMP26 of nontypeable Haemophilus influenzae after acute otitis media in otitis-prone children.
Current and Future Prospects for a Vaccine for Nontypeable Haemophilus influenzae.
Decreased Acute Otitis Media With Treatment Failure After Introduction of the Ten-valent Pneumococcal Haemophilus influenzae Protein D Conjugate Vaccine.
Developing a vaccine to prevent otitis media caused by nontypeable Haemophilus influenzae.
Efficacy of 10-valent pneumococcal non-typeable Haemophilus influenzae protein D conjugate vaccine against acute otitis media and nasopharyngeal carriage in Panamanian children - A randomized controlled trial.
ELISA IgG concentrations and opsonophagocytic activity following pneumococcal protein D conjugate vaccination and relationship to efficacy against acute otitis media.
Haemophilus influenzae-protein D specific antibody correlate with protection against acute otitis media in young children.
Higher levels of mucosal antibody to pneumococcal vaccine candidate proteins are associated with reduced acute otitis media caused by Streptococcus pneumoniae in young children.
Impact of different case definitions for acute otitis media on the efficacy estimates of a pneumococcal conjugate vaccine.
Local and systemic antibody levels against protein D of Haemophilus influenzae following immunization and infection in rats.
Nasopharyngeal carriage of otitis media pathogens in infants receiving 10-valent non-typeable Haemophilus influenzae protein D conjugate vaccine (PHiD-CV10), 13-valent pneumococcal conjugate vaccine (PCV13) or a mixed primary schedule of both vaccines: A randomised controlled trial.
Nontypeable Haemophilus influenzae as a pathogen in children.
Otitis media outcomes of a combined 10-valent pneumococcal Haemophilus influenzae protein D conjugate vaccine and 13-valent pneumococcal conjugate vaccine schedule at 1-2-4-6?months: PREVIX_COMBO, a 3-arm randomised controlled trial.
Passive immunization with human anti-protein D antibodies induced by polysaccharide protein D conjugates protects chinchillas against otitis media after intranasal challenge with Haemophilus influenzae.
Pneumococcal capsular polysaccharides conjugated to protein D for prevention of acute otitis media caused by both Streptococcus pneumoniae and non-typable Haemophilus influenzae: a randomised double-blind efficacy study.
Polysaccharide conjugate vaccine protein carriers as a "neglected valency" - Potential and limitations.
Role of Surfactant Protein D in Experimental Otitis Media.
Substrate binding protein SBP2 of a putative ABC transporter as a novel vaccine antigen of Moraxella catarrhalis.
The Effect of the 10-Valent Pneumococcal Nontypeable Haemophilus influenzae Protein D Conjugate Vaccine on H. influenzae in Healthy Carriers and Middle Ear Infections in Iceland.
Vaccines for Nontypeable Haemophilus influenzae: the Future Is Now.
What the pediatrician should know about non-typeable Haemophilus influenzae.
Ovarian Neoplasms
Surfactant Protein D as a Potential Biomarker and Therapeutic Target in Ovarian Cancer.
Overweight
Least absolute shrinkage and selection operator type methods for the identification of serum biomarkers of overweight and obesity: simulation and application.
Pancreatic Neoplasms
A Recombinant Fragment of Human Surfactant Protein D induces Apoptosis in Pancreatic Cancer Cell Lines via Fas-Mediated Pathway.
Human Surfactant Protein D Suppresses Epithelial-to-Mesenchymal Transition in Pancreatic Cancer Cells by Downregulating TGF-?.
Pancreatitis
Surfactant Protein D Dampens Lung Injury by Suppressing NLRP3 Inflammasome Activation and NF-?B Signaling in Acute Pancreatitis.
Paratuberculosis
An evaluation of selected screening tests for bovine paratuberculosis.
Plague
Antigenic profiling of yersinia pestis infection in the Wyoming coyote (Canis latrans).
Pneumococcal Infections
Biophysical Characterization and Thermal Stability of Pneumococcal Histidine Triad Protein D in the Presence of Zinc and Manganese.
Cost-effectiveness evaluation of the 10-valent pneumococcal non-typeable Haemophilus influenzae protein D conjugate vaccine for children in Taiwan.
Effectiveness of pneumococcal Haemophilus influenzae protein D conjugate vaccine against pneumonia in children: A cluster-randomised trial.
Effectiveness of the 10-valent pneumococcal conjugate vaccine among girls, boys, preterm and low-birth-weight infants - Results from a randomized, double-blind vaccine trial.
Effectiveness of the ten-valent pneumococcal Haemophilus influenzae protein D conjugate vaccine (PHiD-CV10) against invasive pneumococcal disease: a cluster randomised trial.
Global prevailing and emerging pediatric pneumococcal serotypes.
Invasive pneumococcal diseases in birth cohorts vaccinated with PCV-7 and/or PHiD-CV in the province of Quebec, Canada.
Mucosal immunization with polyamine transport protein D (PotD) protects mice against nasopharyngeal colonization with Streptococcus pneumoniae.
Overall effectiveness of pneumococcal conjugate vaccines: an economic analysis of PHiD-CV and PCV-13 in the immunization of infants in Italy.
Protection against pneumococcal infection elicited by immunization with glutamyl tRNA synthetase, polyamine transport protein D and sortase A.
Safety, reactogenicity and immunogenicity of a novel pneumococcal protein-based vaccine in adults: A phase I/II randomized clinical study.
Vaccine effectiveness of the pneumococcal Haemophilus influenzae protein D conjugate vaccine (PHiD-CV10) against clinically suspected invasive pneumococcal disease: a cluster-randomised trial.
Pneumoconiosis
Serum concentrations of Krebs von den Lungen-6, surfactant protein D, and matrix metalloproteinase-2 as diagnostic biomarkers in patients with asbestosis and silicosis: a case-control study.
Pneumocystis Infections
Surfactant protein D enhances Pneumocystis infection in immune-suppressed mice.
Pneumonia
Accumulation of surfactant protein D in the lung during Pneumocystis carinii pneumonia.
Carbohydrate recognition domain of surfactant protein D mediates interactions with Pneumocystis carinii glycoprotein A.
CD4+ T-cell responses among adults and young children in response to Streptococcus pneumoniae and Haemophilus influenzae vaccine candidate protein antigens.
Children with absent surfactant protein D in bronchoalveolar lavage have more frequently pneumonia.
Chronic obstructive pulmonary disease and inhaled steroids alter surfactant protein D (SP-D) levels: a cross-sectional study.
Comparative evaluation of heterologous production systems for recombinant pulmonary surfactant protein D.
Concentration of surfactant protein D, Clara cell protein CC-16 and IL-10 in bronchoalveolar lavage (BAL) in patients with sarcoidosis, hypersensivity pneumonitis and idiopathic pulmonary fibrosis.
Development of an enzyme-linked immunosorbent assay for measurement of rat pulmonary surfactant protein D using monoclonal antibodies.
Effectiveness of pneumococcal Haemophilus influenzae protein D conjugate vaccine against pneumonia in children: A cluster-randomised trial.
Examination of Surfactant Protein D as a Biomarker for Evaluating Pulmonary Toxicity of Nanomaterials in Rat.
HIV Infection and Circulating Levels of Prosurfactant Protein B and Surfactant Protein D.
Impact of 10-valent pneumococcal non-typeable Haemophilus influenzae protein D conjugate vaccine (PHiD-CV) on childhood pneumonia hospitalizations in Brazil two years after introduction.
Increased serum SP-D in identification of high-risk smokers at high risk of COPD.
New Biomarkers to Diagnose Ventilator Associated Pneumonia: Pentraxin 3 and Surfactant Protein D.
Nontypeable Haemophilus influenzae and childhood pneumonia.
Prognostic value of serum surfactant protein D level prior to transplant for the development of bronchiolitis obliterans syndrome and idiopathic pneumonia syndrome following allogeneic hematopoietic stem cell transplantation.
Restoration of lung surfactant protein D by IL-6 protects against secondary pneumonia following hemorrhagic shock.
S-nitrosylation of surfactant protein D as a modulator of pulmonary inflammation.
SP-D, KL-6, and HTI-56 levels in children with mycoplasma pneumoniae pneumonia.
Surfactant protein D (SP-D) serum levels in patients with community-acquired pneumonia small star, filled.
Surfactant protein D and KL-6 as serologic indicators of Pneumocystis carinii pneumonia in a child with acute lymphoblastic leukemia.
Surfactant Protein D Deficiency Aggravates Cigarette Smoke-Induced Lung Inflammation by Upregulation of Ceramide Synthesis.
Surfactant protein D-mediated aggregation of Pneumocystis carinii impairs phagocytosis by alveolar macrophages.
Surfactant protein D: a predictor for severity of community-acquired pneumonia in children.
Surfactant protein D: a useful marker for differentiation of drug-induced pneumonia and bacterial pneumonia.
Update on Molecular Mechanisms of Corticosteroid Resistance in Chronic Obstructive Pulmonary Disease.
[Increased level of KL-6 in a BJP-?-type multiple myeloma patient with poor prognosis].
Pneumonia, Bacterial
Evaluation of serum amyloid a and surfactant protein D in sera for identification of the clinical condition of horses with bacterial pneumonia.
Surfactant protein D: a useful marker for differentiation of drug-induced pneumonia and bacterial pneumonia.
Pneumonia, Pneumococcal
The role of surfactant protein D in the colonisation of the respiratory tract and onset of bacteraemia during pneumococcal pneumonia.
Pneumonia, Pneumocystis
Accumulation of surfactant protein D in the lung during Pneumocystis carinii pneumonia.
Carbohydrate recognition domain of surfactant protein D mediates interactions with Pneumocystis carinii glycoprotein A.
Surfactant protein D and KL-6 as serologic indicators of Pneumocystis carinii pneumonia in a child with acute lymphoblastic leukemia.
Surfactant protein D-mediated aggregation of Pneumocystis carinii impairs phagocytosis by alveolar macrophages.
Pneumonia, Ventilator-Associated
Murepavadin activity tested against contemporary (2016-17) clinical isolates of XDR Pseudomonas aeruginosa.
Poliomyelitis
Safety of the 11-valent pneumococcal vaccine conjugated to non-typeable Haemophilus influenzae-derived protein D in the first 2 years of life and immunogenicity of the co-administered hexavalent diphtheria, tetanus, acellular pertussis, hepatitis B, inactivated polio virus, Haemophilus influenzae type b and control hepatitis A vaccines.
Pre-Eclampsia
Differential levels of surfactant protein A, surfactant protein D, and progesterone to estradiol ratio in maternal serum before and after the onset of severe early-onset preeclampsia.
Precursor Cell Lymphoblastic Leukemia-Lymphoma
Surfactant protein D and KL-6 as serologic indicators of Pneumocystis carinii pneumonia in a child with acute lymphoblastic leukemia.
Premature Birth
A study of collectin genes in spontaneous preterm birth reveals an association with a common surfactant protein D gene polymorphism.
Genetic associations of surfactant protein D and angiotensin-converting enzyme with lung disease in preterm neonates.
Surfactant protein D modulates levels of IL-10 and TNF-? in intrauterine compartments during lipopolysaccharide-induced preterm birth.
Prostatic Neoplasms
Membrane Interactome of a Recombinant Fragment of Human Surfactant Protein D Reveals GRP78 as a Novel Binding Partner in PC3, a Metastatic Prostate Cancer Cell Line.
Pruritus
Auf1/Hnrnpd-deficient mice develop pruritic inflammatory skin disease.
Psoriasis
Surfactant protein D in atopic dermatitis and psoriasis.
Pulmonary Alveolar Proteinosis
Accumulation of surfactant protein D in human pulmonary alveolar proteinosis.
Clinical importance of bronchoalveolar lavage fluid and blood cytokines, surfactant protein D, and Kerbs von Lungren 6 antigen in idiopathic pulmonary alveolar proteinosis.
Lung surfactant levels are regulated by Ig-Hepta/GPR116 by monitoring surfactant protein D.
Structure and activity of human surfactant protein D from different natural sources.
Pulmonary Atelectasis
A case of progressive orthopnoea and shoulder pain secondary to bilateral diaphragmatic paralysis.
Pulmonary Disease, Chronic Obstructive
"Protein biomarkers for COPD outcomes".
Association of Surfactant-Associated Protein D Gene Polymorphisms with the Risk of COPD: a Meta-Analysis.
Biomarkers for chronic obstructive pulmonary disease: surfactant protein D and C-reactive protein.
Biomarkers in airway diseases.
Chronic obstructive pulmonary disease and inhaled steroids alter surfactant protein D (SP-D) levels: a cross-sectional study.
Cigarette smoking prior to blood sampling acutely affects serum levels of the chronic obstructive pulmonary disease biomarker surfactant protein D.
Circulating surfactant protein D as a potential lung-specific biomarker of health outcomes in COPD: a pilot study.
Common Genetic Polymorphisms Influence Blood Biomarker Measurements in COPD.
Comprehensive analysis of gene-expression profile in chronic obstructive pulmonary disease.
Comprehensive characterisation of pulmonary and serum surfactant protein D in COPD.
Correlation analysis of surfactant protein A and surfactant protein D with lung function in exhaled breath condensate from lung cancer patients with and without COPD.
Effect of Single versus Bilateral Lung Transplantation on Plasma Surfactant Protein D Levels in Idiopathic Pulmonary Fibrosis.
Evaluation of full-length, cleaved and nitrosylated serum surfactant protein D as biomarkers for COPD.
Genetic Polymorphisms of Surfactant Protein D rs2243639, Interleukin (IL)-1? rs16944 and IL-1RN rs2234663 in Chronic Obstructive Pulmonary Disease, Healthy Smokers, and Non-Smokers.
Genetic Variants in IL6R and ADAM19 are Associated with COPD Severity in a Mexican Mestizo Population.
Increased MMP8 Levels in Atopic Chronic Obstructive Pulmonary Disease: A Study Testing Multiple Immune Factors in Atopic and Non-Atopic Patients.
Integrating lung and plasma expression of pneumo-proteins in developing biomarkers in COPD: a case study of surfactant protein D.
Involvement of surfactant protein D in emphysema revealed by genetic association study.
Nicotinic acetylcholine receptors (rs1051730) gene polymorphism and surfactant protein D level in chronic obstructive pulmonary disease.
Non-typeable Haemophilus influenzae protein vaccine in adults with COPD: A phase 2 clinical trial.
Perinatal biomarkers implying 'Developmental Origins of Health and Disease' consequences in intrauterine growth restriction.
Polymorphisms in Surfactant Protein D are Associated with COPD.
Prognostic significance of surfactant protein A, surfactant protein D, Clara cell protein 16, S100 protein, trefoil factor 3, and prostatic secretory protein 94 in idiopathic pulmonary fibrosis, sarcoidosis, and chronic pulmonary obstructive disease.
Role of serum and induced sputum surfactant protein D in predicting the response to treatment in chronic obstructive pulmonary disease.
Serum biomarkers and outcomes in patients with moderate COPD: a substudy of the randomised SUMMIT trial.
Serum surfactant protein D during acute exacerbations of chronic obstructive pulmonary disease.
Serum Surfactant Protein D is a Potential Biomarker for Chronic Obstructive Pulmonary Disease: a Systematic Review and Meta-analysis.
Serum surfactant protein D is steroid sensitive and associated with exacerbations of COPD.
Serum surfactant protein D, lung function decline, and incident chronic obstructive pulmonary disease: a longitudinal study in Beijing.
Serum surfactant protein D: biomarker of chronic obstructive pulmonary disease.
Simvastatin Therapy and Bronchoalveolar Lavage Fluid Biomarkers in Chronic Obstructive Pulmonary Disease.
Smoking reduces surfactant protein D and phospholipids in patients with and without chronic obstructive pulmonary disease.
SNP rs3088308 is a risk factor for poor lung function in healthy smokers.
SP-D polymorphisms and the risk of COPD.
Surfactant protein D as a biomarker for chronic obstructive pulmonary disease.
Surfactant protein D in chornic obstructive pulmonary disease (COPD).
Surfactant protein D is a causal risk factor for COPD: results of Mendelian randomisation.
Surfactant protein D multimerization and gene polymorphism in COPD and asthma.
Surfactant protein D, a clinical biomarker for chronic obstructive pulmonary disease with excellent discriminant values.
Surfactant protein D, Club cell protein 16, Pulmonary and activation-regulated chemokine, C-reactive protein, and Fibrinogen biomarker variation in chronic obstructive lung disease.
Surfactant protein d, soluble intercellular adhesion molecule-1 and high-sensitivity C-reactive protein as biomarkers of chronic obstructive pulmonary disease.
Systematic Review and Meta-Analysis Confirms Significant Contribution of Surfactant Protein D in Chronic Obstructive Pulmonary Disease.
The Effect of Intrauterine Growth Restriction on Circulating Surfactant Protein D Concentrations in the Perinatal Period.
The EFFECT trial: evaluating exacerbations, biomarkers, and safety outcomes with two dose levels of fluticasone propionate/formoterol in COPD.
The PROTECCT-M study: a cohort study investigating associations between novel specific biomarkers, patient-related, healthcare system markers and the trajectory of COPD patients treated in primary care.
The relationship between serum levels of surfactant protein D in COPD exacerbation severity and mortality
The role of serum surfactant protein D as a biomarker of exacerbation of chronic obstructive pulmonary disease.
Value of serum and induced sputum surfactant protein-D in chronic obstructive pulmonary disease.
[Effect of basic therapy on clinical symptoms, quality of life and systemic inflammation in patients with chronic obstructive pulmonary disease].
Pulmonary Edema
Prognostic value of surfactant proteins A and D in patients with acute lung injury.
Pulmonary Embolism
The effectiveness of the serum surfactant protein D (Sp-D) level to indicate lung injury in pulmonary embolism.
Pulmonary Emphysema
A recombinant fragment of human surfactant protein D reduces alveolar macrophage apoptosis and pro-inflammatory cytokines in mice developing pulmonary emphysema.
Surfactant protein D regulates NF-kappa B and matrix metalloproteinase production in alveolar macrophages via oxidant-sensitive pathways.
Pulmonary Fibrosis
Clinical significance of surfactant protein D as a serum marker for evaluating pulmonary fibrosis in patients with systemic sclerosis.
MFAP4: a candidate biomarker for hepatic and pulmonary fibrosis?
Nintedanib modulates surfactant protein-D expression in A549 human lung epithelial cells via the c-Jun N-terminal kinase-activator protein-1 pathway.
Prognostic significance of surfactant protein A, surfactant protein D, Clara cell protein 16, S100 protein, trefoil factor 3, and prostatic secretory protein 94 in idiopathic pulmonary fibrosis, sarcoidosis, and chronic pulmonary obstructive disease.
Serum pulmonary and activation-regulated chemokine/CCL18 levels in patients with systemic sclerosis: a sensitive indicator of active pulmonary fibrosis.
The Diagnostic Value of the Interstitial Biomarkers KL-6 and SP-D for the Degree of Fibrosis in Combined Pulmonary Fibrosis and Emphysema.
[Clinical value of surfactant protein D as a biomarker of pulmonary fibrosis in patients with scleroderma systematica in relation to the presence of gastroesophageal reflux].
Radiation Fibrosis Syndrome
Monoclonal antibodies to surfactant protein D: evaluation of immunoreactivity in normal rat lung and in a radiation-induced fibrosis model.
Radiation Pneumonitis
Clarithromycin mitigates radiation pneumonitis in patients with lung cancer treated with stereotactic body radiotherapy.
Measurement of exhaled nitric oxide and serum surfactant protein D levels for monitoring radiation pneumonitis following thoracic radiotherapy.
Radiation pneumonitis after stereotactic radiation therapy for lung cancer.
Renal Insufficiency, Chronic
Serum surfactant protein D is associated with the prognosis in patients with chronic kidney disease.
Reperfusion Injury
Change of surfactant protein D and A after renal ischemia reperfusion injury.
Reproductive Tract Infections
The Chlamydia trachomatis PmpD adhesin forms higher order structures through disulphide-mediated covalent interactions.
Respiratory Distress Syndrome
Evaluation of Lung Injury in Infants with Congenital Diaphragmatic Hernia.
Hypoxemic Patients With Bilateral Infiltrates Treated With High-Flow Nasal Cannula Present a Similar Pattern of Biomarkers of Inflammation and Injury to Acute Respiratory Distress Syndrome Patients.
Serum surfactant protein D in COVID-19 is elevated and correlated with disease severity.
Surfactant Protein D Is Altered in Experimental Malaria-Associated Acute Lung Injury/Acute Respiratory Distress Syndrome.
Surfactant Protein D Is Associated With Severe Pediatric ARDS, Prolonged Ventilation, and Death in Children With Acute Respiratory Failure.
The Association between Body Mass Index and Plasma Cytokine Levels in Patients with Acute Lung Injury.
[Serial changes in biomarkers in pulmonary and extrapulmonary acute respiratory distress syndrome].
Respiratory Insufficiency
Association of patient weight status with plasma surfactant protein D, a biomarker of alveolar epithelial injury, in children with acute respiratory failure.
Respiratory Syncytial Virus Infections
A recombinant trimeric surfactant protein D carbohydrate recognition domain inhibits respiratory syncytial virus infection in vitro and in vivo.
Surfactant protein D gene polymorphism associated with severe respiratory syncytial virus infection.
Respiratory Tract Infections
Effectiveness of the ten-valent pneumococcal Haemophilus influenzae protein D conjugate vaccine (PHiD-CV10) against all respiratory tract infections in children under two years of age.
Effects on the ciliated epithelium of protein D-producing and -nonproducing nontypeable Haemophilus influenzae in nasopharyngeal tissue cultures.
Impact of surfactant protein D, interleukin-5, and eosinophilia on Cryptococcosis.
Respiratory tract infections in diabetic and non-diabetic individuals are linked with serum surfactant protein-D.
The Effect of Intrauterine Growth Restriction on Circulating Surfactant Protein D Concentrations in the Perinatal Period.
Rhinitis, Allergic
Association between single nucleotide polymorphisms of surfactant protein D and allergic rhinitis in Chinese patients.
[Expression and significance of pulmonary surfactant protein D and IL-16 in allergic rhinitis and nasal polyps].
Salmonella Infections
SopD from Salmonella specifically inactivates Rab8.
Sarcoidosis
Concentration of surfactant protein D, Clara cell protein CC-16 and IL-10 in bronchoalveolar lavage (BAL) in patients with sarcoidosis, hypersensivity pneumonitis and idiopathic pulmonary fibrosis.
Elevation of surfactant protein D, a pulmonary disease biomarker, in the sera of uveitis patients with sarcoidosis.
Prognostic significance of surfactant protein A, surfactant protein D, Clara cell protein 16, S100 protein, trefoil factor 3, and prostatic secretory protein 94 in idiopathic pulmonary fibrosis, sarcoidosis, and chronic pulmonary obstructive disease.
Scleroderma, Systemic
Can serum surfactant protein D or CC-chemokine ligand 18 predict outcome of interstitial lung disease in patients with early systemic sclerosis?
Clinical significance of surfactant protein D as a serum marker for evaluating pulmonary fibrosis in patients with systemic sclerosis.
Comprehensive investigation of novel serum markers of pulmonary fibrosis associated with systemic sclerosis and dermato/polymyositis.
Serum concentration of surfactant protein D in patients with systemic sclerosis: The potential marker of the interstitial lung disease severity.
Serum pulmonary and activation-regulated chemokine/CCL18 levels in patients with systemic sclerosis: a sensitive indicator of active pulmonary fibrosis.
Serum surfactant protein D and exhaled nitric oxide as biomarkers of early lung damage in systemic sclerosis.
Surfactant protein D (SP-D) and systemic scleroderma (SSc).
Surfactant protein D and KL-6 serum levels in systemic sclerosis: correlation with lung and systemic involvement.
Sepsis
MEG3 Alleviated LPS-Induced Intestinal Injury in Sepsis by Modulating miR-129-5p and Surfactant Protein D.
miR-182-5p contributes to intestinal injury in a murine model of Staphylococcus aureus pneumonia-induced sepsis via targeting surfactant protein D.
miR-199a-5p Exacerbated Intestinal Barrier Dysfunction through Inhibiting Surfactant Protein D and Activating NF-?B Pathway in Sepsis.
S1P lyase inhibition protects against sepsis by promoting disease tolerance via the S1P/S1PR3 axis.
Surfactant protein D (SP-D) gene polymorphism rs721917 is an independent predictor of acute kidney injury development in sepsis patients: a prospective cohort study.
Surfactant protein D attenuates acute lung and kidney injuries in pneumonia-induced sepsis through modulating apoptosis, inflammation and NF-?B signaling.
Sexually Transmitted Diseases
From the Cover: Chlamydia trachomatis polymorphic membrane protein D is a species-common pan-neutralizing antigen.
Shock, Septic
Association of type II secretory phospholipase A2 and surfactant protein D with the pulmonary oxygenation potential in patients with septic shock during polymyxin-B immobilized fiber-direct hemoperfusion.
Intratracheal recombinant surfactant protein d prevents endotoxin shock in the newborn preterm lamb.
Silicosis
Serum concentrations of Krebs von den Lungen-6, surfactant protein D, and matrix metalloproteinase-2 as diagnostic biomarkers in patients with asbestosis and silicosis: a case-control study.
[Association of surfactant protein D gene polymorphisms at rs3088308 and rs721917 with susceptibility to silicosis].
Sleep Apnea, Obstructive
Potential inflammatory markers in obstructive sleep apnea-hypopnea syndrome.
Spinocerebellar Ataxias
Phospholipid-metabolizing enzymes in Alzheimer's disease: increased lysophospholipid acyltransferase activity and decreased phospholipase A2 activity.
Squamous Cell Carcinoma of Head and Neck
Opposite effects of tumor protein D (TPD) 52 and TPD54 on oral squamous cell carcinoma cells.
Staphylococcal Infections
Protective Role of Surfactant Protein D in Ocular Staphylococcus aureus Infection.
Starvation
Evidence of the involvement of an outer membrane protein in DNA initiation.
Suppuration
Reduced nontypeable Haemophilus influenzae lower airway infection in children with chronic endobronchial suppuration vaccinated with the 10-valent pneumococcal H. influenzae protein D conjugate vaccine.
Tetanus
A physico-chemical assessment of the thermal stability of pneumococcal conjugate vaccine components.
Comparative effects of carrier proteins on vaccine-induced immune response.
Effectiveness of the ten-valent pneumococcal Haemophilus influenzae protein D conjugate vaccine (PHiD-CV10) against invasive pneumococcal disease: a cluster randomised trial.
Immunogenicity and safety of a booster dose of the 10-valent pneumococcal Haemophilus influenzae protein D conjugate vaccine coadministered with the tetravalent meningococcal serogroups A, C, W-135 and Y tetanus toxoid conjugate vaccine in toddlers: a randomized trial.
Immunogenicity, safety, and reactogenicity of the 10-valent pneumococcal non-typeable Hemophilus influenzae protein D conjugate vaccine (PHiD-CV) when co-administered with the DTPw-HBV/Hib vaccine in Indian infants: a single-blind, randomized, controlled study.
Pneumococcal conjugated vaccine: PHiD-CV.
Preclinical studies on new proteins as carrier for glycoconjugate vaccines.
Protein carriers of conjugate vaccines: Characteristics, development and clinical trials.
Safety and reactogenicity of primary vaccination with the 10-valent pneumococcal non-typeable Haemophilus influenzae protein D conjugate vaccine in Vietnamese infants: a randomised, controlled trial.
Safety of the 11-valent pneumococcal vaccine conjugated to non-typeable Haemophilus influenzae-derived protein D in the first 2 years of life and immunogenicity of the co-administered hexavalent diphtheria, tetanus, acellular pertussis, hepatitis B, inactivated polio virus, Haemophilus influenzae type b and control hepatitis A vaccines.
The short-term impact of each primary dose of pneumococcal conjugate vaccine on nasopharyngeal carriage: Systematic review and meta-analyses of randomised controlled trials.
Trachoma
From the Cover: Chlamydia trachomatis polymorphic membrane protein D is a species-common pan-neutralizing antigen.
Tuberculosis
Critical Role of Amino Acid Position 343 of Surfactant Protein-D in the Selective Binding of Glycolipids from Mycobacterium tuberculosis.
Functional Analysis of Genetic Variations in Surfactant Protein D in Mycobacterial Infection and Their Association With Tuberculosis.
Paediatric and adult bronchiectasis: Vaccination in prevention and management.
Surfactant protein D binds to Mycobacterium tuberculosis bacilli and lipoarabinomannan via carbohydrate-lectin interactions resulting in reduced phagocytosis of the bacteria by macrophages.
Surfactant protein D increases fusion of Mycobacterium tuberculosis-containing phagosomes with lysosomes in human macrophages.
Surfactant protein D inhibition of human macrophage uptake of Mycobacterium tuberculosis is independent of bacterial agglutination.
The evaluation of serum surfactant protein D (SP-D) levels as a biomarker of lung injury in tuberculosis and different lung diseases.
Turner Syndrome
The effects of GH and hormone replacement therapy on serum concentrations of mannan-binding lectin, surfactant protein D and vitamin D binding protein in Turner syndrome.
Uveitis
Elevation of surfactant protein D, a pulmonary disease biomarker, in the sera of uveitis patients with sarcoidosis.
Vaccinia
Protective effect of surfactant protein d in pulmonary vaccinia virus infection: implication of a27 viral protein.
Vascular Diseases
Increased circulating levels of soluble Fas ligand are correlated with disease activity in patients with fibrosing lung diseases.
Ventilator-Induced Lung Injury
Increased prevalence of low oligomeric state surfactant protein D with restricted lectin activity in bronchoalveolar lavage fluid from preterm infants.
Virus Diseases
A recombinant trimeric surfactant protein D carbohydrate recognition domain inhibits respiratory syncytial virus infection in vitro and in vivo.
Hapivirins and Diprovirins: Novel ?-Defensin Analogs with Potent Activity against Influenza A Virus.
Protective effect of surfactant protein d in pulmonary vaccinia virus infection: implication of a27 viral protein.
Pulmonary surfactant phosphatidylglycerol inhibits respiratory syncytial virus-induced inflammation and infection.
Pulmonary Surfactant Protein D in First-Line Innate Defence against Influenza A Virus Infections.
Serum Surfactant Protein D (SP-D) is a Prognostic Marker of Poor Outcome in Patients with A/H1N1 Virus Infection.
Surfactant protein D gene polymorphism associated with severe respiratory syncytial virus infection.
Whooping Cough
Antibody Persistence in Young Children 5 Years after Vaccination with a Combined Haemophilus influenzae Type b-Neisseria meningitidis Serogroup C Conjugate Vaccine Coadministered with Diphtheria-Tetanus-Acellular Pertussis-Based and Pneumococcal Conjugate Vaccines.
Immunogenicity and safety of the 10-valent pneumococcal nontypeable Haemophilus influenzae protein D conjugate vaccine (PHiD-CV) co-administered with DTPa vaccine in Japanese children: A randomized, controlled study.
Immunogenicity, safety, and reactogenicity of the 10-valent pneumococcal non-typeable Hemophilus influenzae protein D conjugate vaccine (PHiD-CV) when co-administered with the DTPw-HBV/Hib vaccine in Indian infants: a single-blind, randomized, controlled study.
Paediatric and adult bronchiectasis: Vaccination in prevention and management.
Safety and reactogenicity of primary vaccination with the 10-valent pneumococcal non-typeable Haemophilus influenzae protein D conjugate vaccine in Vietnamese infants: a randomised, controlled trial.
Safety of the 11-valent pneumococcal vaccine conjugated to non-typeable Haemophilus influenzae-derived protein D in the first 2 years of life and immunogenicity of the co-administered hexavalent diphtheria, tetanus, acellular pertussis, hepatitis B, inactivated polio virus, Haemophilus influenzae type b and control hepatitis A vaccines.
Yellow Fever
Immunogenicity of pneumococcal conjugate vaccine formulations containing pneumococcal proteins, and immunogenicity and reactogenicity of co-administered routine vaccines - A phase II, randomised, observer-blind study in Gambian infants.